{"id":840491,"date":"2025-04-23T07:11:52","date_gmt":"2025-04-23T11:11:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions\/"},"modified":"2025-04-23T07:11:52","modified_gmt":"2025-04-23T11:11:52","slug":"labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions\/","title":{"rendered":"Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Labcorp\u00ae<\/sup> Plasma Detect\u2122 now available for clinical use to assess risk of recurrence in stage III colon cancer patients<\/i>\n <\/p>\n

\n FDA-authorized liquid biopsy assay PGDx elio\u00ae<\/sup> plasma focus\u2122 Dx now available to support treatment selection<\/i>\n <\/p>\n

\n
\n BURLINGTON, N.C.<\/span>
\n <\/span>, April 23, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Labcorp<\/a>\u00a0(NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect<\/a>\u00a0for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx<\/a>, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.<\/p>\n

\n

\n
\n \"Photo
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Labcorp is dedicated to providing oncologists with a comprehensive portfolio of innovative solutions that enable precise, timely and personalized treatment decisions,” said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. “With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we’re advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.”<\/p>\n

\n Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer Patients
<\/b>
\n Stage III colon cancer has a nearly <\/span>
\n 30%<\/a>
\n \u00a0recurrence rate within five years. <\/span>
\n Labcorp Plasma Detect<\/a>
\n \u00a0is a blood-based test using whole-genome sequencing (<\/span>WGS) to detect circulating tumor DNA (<\/span>ctDNA), indicating the presence of molecular residual disease (<\/span>MRD).i<\/sup> Patients who are\u00a0<\/span>MRD-positive after cancer treatment have a higher risk of recurrence and a poorer prognosis. <\/span>Labcorp’s test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy.<\/span><\/p>\n

Key Features of Labcorp Plasma Detect:<\/p>\n